Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/4/2019
SIETES contiene 92717 citas

 
 
 1 a 10 de 10 
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas
Barnett AH, O'Hare P. Incretins and pancreatic cancer. Cardiovascular benefits in incretins. BMJ 2013;347:24-5. [Ref.ID 96132]
2.Tiene citas relacionadas
Tahrani AA, Bailey CJ, Barnett AH. Insulin degludec: a new ultra-longacting insulin. Lancet 2012;379:1465-9. [Ref.ID 92727]
3. Cita con resumen
Farmer AJ, Perera R, Ward A, Heneghan C, Oke J, Barnett AH, Davidson MB, Guerci B, Coates V, Schwedes U, O'Malley S. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ 2012;344:14. [Ref.ID 92516]
4.
Tahrani AA, Bailey C, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011;378:182-97. [Ref.ID 90871]
5. Cita con resumen
Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L, for the ISICA group. The International Study of Insulin and Cancer. Lancet 2010;376:769-70. [Ref.ID 89311]
6. Cita con resumen
Bailey CJ, Barnett AH. Why is Exubera being withdrawn?. BMJ 2007;335:1156. [Ref.ID 81672]
7.Tiene citas relacionadas
Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, for the Diabetics Exposed to Telmisartan and Enalapril Study Group. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1952-61. [Ref.ID 71799]
8.
Barnett AH. Recent trends in insulin therapy. Prescr J 1998;38:107-14. [Ref.ID 38665]
9.
Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47-51. [Ref.ID 30578]
10.
Barnett AH, Leslie D, Watkins PJ. Con insulin-treated diabetics be given beta-adrenergic blocking drugs?. BMJ 1980;280:976-8. [Ref.ID 6226]
Seleccionar todas
 
 1 a 10 de 10